

## **Supplementary Methods**

**Western Blot.** PyMT-WT and EO771 cell lysates were generated and protein expression analysed by Western blotting as previously described (9). Antibody details listed in antibody section.

**Conditioned media assays.** Conditioned media was generated by filtering (0.22 µm filter, Millipore) serum-free, phenol red-free low glucose Dulbecco's Modified Eagles Medium (Invitrogen) cultured on confluent EO771, PyMT-WT or PyMT-Siah2<sup>-/-</sup> cells plated in 6-well plates for 10 hrs under normoxic (20% O<sub>2</sub>) or hypoxic conditions (2% O<sub>2</sub>) as previously described (6). To generate the pre-metastatic niche in the lung *in vivo* and for studies of BMDC lung infiltration, conditioned media (300 µl) was injected daily for 7 days (day 0-6) into the peritoneum of immune competent WT or eGFP bone marrow-chimeric mice, and lungs harvested the next day (day 7) for flow cytometry analysis or embedding in OCT (Tissue-Tek).

**Experimental metastasis models.** Mice were injected with 2 x 10<sup>5</sup> EO771/PyMT-WT Cherry or B16F10 cells intravenously via the tail vein on day 7 after treatment with conditioned medium for 7 days. Lungs were harvested 2-4 weeks later and analyzed by flow cytometry for Cherry positive tumor cells in EO771 and PyMT-WT models. In B16F10 models, macrometastatic foci in whole lungs was counted using a dissecting microscope, and micrometastatic foci counted in a similar manner on H&E stained-lung sections.

**MCP-1/CCL2 neutralization.** Conditioned medium was incubated with anti-MCP-1 antibody at 40 ng/ml for 90 min at room temperature on a rotating wheel. The antibody was then removed from the conditioned medium by incubation with 50 µl Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnologies) per 20 ml conditioned medium on rotating wheel for 1 hour at room temperature. Samples were centrifuged at 1400 rpm for 4 min to pellet beads. Conditioned medium neutralized with an MCP-1 antibody was then injected into immune competent WT mice in place of normal conditioned medium as above.

**NK cell depletion.** Immune competent WT mice were treated as above with additional intraperitoneal injections of 100 µg asialoGM1 (rabbit; Wako Pure Chemical Industries), or isotype Ig antibody on days -1, 0, 7, 14, 21 and 28. Eyebleeds were done on day 0 and 7 to confirm NK cell depletion via flow cytometry analysis, and  $2 \times 10^5$  Cherry-positive tumor cells were injected intravenously on day 7. Mice were harvested on day 35 and whole lung analyzed by flow cytometry.

**Antibodies.** Antibodies used in Western blot, neutralization and flow cytometry analysis are listed below.

<b>Antibody</b>	<b>Details</b>	<b>Source</b>
Hif-1 $\alpha$	Rabbit anti-mouse pAb	Novus Biologicals
Hif-2 $\alpha$	Rabbit anti-mouse pAb	Novus Biologicals
$\alpha$ -Tubulin	Mouse anti-mouse mAb	Sigma Aldrich
MCP-1	Anti-mouse CCL2/JE/MCP-1 pAb	R&D Systems
GM1	Rabbit anti-asialo GM1	Wako Pure Chemical Industries, Ltd.
CD45.2	Clone 104	eBioscience
CD11b	Clone M1/70	eBioscience
Gr-1	Clone RB6-8C5	eBioscience
Ly6G	Clone 1A8	BD Bioscience
Ly6C	Clone AL-21	BD Bioscience
CD3e	Clone 145-2C11	eBioscience
NK1.1	Clone PK136	eBioscience
CD4	Clone RM4-5	eBioscience
CD8 $\alpha$	Clone 53-6.7	eBioscience
F4/80	Clone BM8	eBioscience
MCH Class II	Clone M5/114.15.2	eBioscience
CD11c	Clone N418	eBioscience
CD69	Clone H1.2F3	eBioscience
CD27	Clone LG.7F9	eBioscience